Tasimelteon: all 26 studies that test it

Page 1 of 1. Open to participants first (2), then studies with results posted, then the rest; newest registration first within each.

• Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric InsomniaRecruitingNCT06953869Phase 3
• Evaluating the Effects of Tasimelteon Vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) and the CRY1Δ11 VariantRecruitingNCT06701396Phase 3
• Evaluating the Effects of Tasimelteon vs. Placebo on Jet Lag Type InsomniaCompletedNCT03373201Phase 3Results posted
• A Proof of Concept Study to Evaluate the Effects of Tasimelteon and Placebo in Travelers With Jet Lag DisorderCompletedNCT03291041Phase 2Results posted
• Open Label Study to Assess the Absolute Bioavailability of Tasimelteon (HETLIOZ™)CompletedNCT02130999Phase 4Results posted
• Withdrawal Study to Demonstrate the Maintenance Effect in the Treatment of Non-24-Hour Sleep-Wake DisorderCompletedNCT01430754Phase 3Results posted
• Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive DisorderCompletedNCT01428661Phase 2/3Results posted
• Efficacy and Safety of Tasimelteon Compared With Placebo in Totally Blind Subjects With Non-24-Hour Sleep-Wake DisorderCompletedNCT01163032Phase 3Results posted
• VEC-162 Study in Adult Patients With Primary InsomniaCompletedNCT00548340Phase 3Results posted
• Safety and Efficacy of VEC-162 on Circadian Rhythm in Healthy Adult VolunteersCompletedNCT00490945Phase 2Results posted
• VEC-162 Study in Healthy Adult Volunteers in a Model of InsomniaCompletedNCT00291187Phase 3Results posted
• Evaluation of Next-Day Residual Effects of Tasimelteon Compared With Placebo and Active Control in Healthy SubjectsCompletedNCT06323655Phase 1
• The Effects of Tasimelteon in Participants With REM Behavior Disorder (RBD)TerminatedNCT05922995Early Phase 1
• Bioequivalence Study Between Tasimelteon Capsule Formulation and Liquid Suspension Formulation in Healthy VolunteersCompletedNCT05572281Phase 1
• Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD)CompletedNCT04652882Phase 3
• Study of the Pharmacokinetics and Safety of Tasimelteon in Children and AdolescentsCompletedNCT02776215Phase 1
• Evaluating the Effects of Tasimelteon vs Placebo on Sleep Disturbances in SMSCompletedNCT02231008Phase 2/3
• Pharmacokinetics of Tasimelteon Alone and in Combination With a CYP3A4 Inhibitor, Ketoconazole, or a CYP3A4 Inducer, Rifampin.CompletedNCT01637636Phase 1
• Evaluation of the Pharmacodynamic and Pharmacokinetic Interactions of Tasimelteon and EthanolCompletedNCT01578057Phase 1
• Pharmacokinetics of Tasimelteon Alone and in Combination With CYP1A2 Inhibitor, FluvoxamineCompletedNCT01540500Phase 1
• Pharmacokinetics of Tasimelteon in Subjects With Renal Impairment and Matched Control Subjects With Relatively Normal Renal FunctionCompletedNCT01526746Phase 1
• Effects of Smoking, Age and Body Size on Pharmacokinetics, Safety and Tolerability on Tasimelteon in Healthy SubjectsCompletedNCT01477619Phase 1
• Tasimelteon for the Treatment of Non-24-hour Sleep-Wake Disorder (N24HSWD) in Blind Individuals With no Light PerceptionCompletedNCT01429116Phase 3
• A Study to Assess the Effect Tasimelteon on the Cytochrome P450 3A4 and 2C8 Enzymes in Healthy SubjectsCompletedNCT01402076Phase 1
• Pharmacokinetics of Tasimelteon in Subjects With Mild or Moderate Hepatic ImpairmentCompletedNCT01271387Phase 1
• Safety Study of Tasimelteon for Treatment of Non-24-Hour-Sleep-Wake Disorder in Blind Individuals With No Light PerceptionActive, not recruitingNCT01218789Phase 3

← Tasimelteon overview